Neoadjuvant vs Adjuvant Therapy for Resectable Pancreatic Cancer: The Evolving Role of Radiation

Seminars in Radiation Oncology

Volumn 24, Issue 2, 2014, Pages 113-125

  Hoffe, Sarah ^a   Rao, Nikhil ^a   Shridhar, Ravi ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; FLUOROURACIL; GEMCITABINE;

ADJUVANT CHEMORADIOTHERAPY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; HEALTH CARE QUALITY; HUMAN; INTERMETHOD COMPARISON; PANCREAS CANCER; PANCREATICODUODENECTOMY; PORTAL VEIN OBSTRUCTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIATION FIELD; REVIEW; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROCEDURES;

CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84895899995     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.11.002     Document Type: Review

References (114)

1. Altekruse S., Kosary C., Krapcho M., et al. SEER cancer statistics review, 1975-2007 2010, 7. National Cancer Institute, Bethesda, MD.
2. Muniraj T., Barve P. Laparoscopic staging and surgical treatment of pancreatic cancer. North Am J Med Sci 2013, 5:1-9.
3. Abrams R.A., Lowy A.M., O'Reilly E.M., et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement. Ann Surg Oncol 2009, 16:1751-1756.
4. Mao C., Domenico D.R., Kim K., et al. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg 1995, 130:125-134.
5. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3496-3502.
6. Oberstein P.E., Olive K.P. Pancreatic cancer: Why is it so hard to treat?. Ther Adv Gastroenterol 2013, 6:321-337.
7. Fernandez-del Castillo C., Morales-Oyarvide V., McGrath D., et al. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery 2012, 152:S56-S63.
8. Turaga K., Kaushik M., Forse R.A., et al. In hospital outcomes after pancreatectomies: An analysis of a national database from 1996 to 2004. J Surg Oncol 2008, 98:156-160.
9. Birkmeyer J.D., Siewers A.E., Finlayson E.V., et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002, 346:1128-1137.
10. Strijker M., van Santvoort H.C., Besselink M.G., et al. Robot-assisted pancreatic surgery: A systematic review of the literature. HPB (Oxford) 2013, 15:1-10.
11. Tamm E.P., Bhosale P.R., Vikram R., et al. Imaging of pancreatic ductal adenocarcinoma: State of the art. World J Radiol 2013, 5:98-105.
12. Kim T., Murakami T., Takahashi S., et al. Pancreatic CT imaging: Effects of different injection rates and doses of contrast material. Radiology 1999, 212:219-225.
13. Prokesch R.W., Chow L.C., Beaulieu C.F., et al. Local staging of pancreatic carcinoma with multi-detector row CT: Use of curved planar reformations initial experience. Radiology 2002, 225:759-765.
14. Valls C., Andia E., Sanchez A., et al. Dual-phase helical CT of pancreatic adenocarcinoma: Assessment of resectability before surgery. Am J Roentgenol 2002, 178:821-826.
15. Pakzad F., Groves A.M., Ell P.J. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 2006, 36:248-256.
16. Bares R., Klever P., Hauptmann S., et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994, 192:79-86.
17. Farma J.M., Santillan A.A., Melis M., et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008, 15:2465-2471.
18. Yao J., Gan G., Farlow D., et al. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours. ANZ J Surg 2012, 82:140-144.
19. Pisters P.W., Lee J.E., Vauthey J.N., et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001, 88:325-337.
20. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2010, 77:1420-1425.
21. 18F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys 2013, 85:1375-1382.
22. Mehta V.K., Fisher G., Ford J.A., et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001, 5:27-35.
23. Allema J.H., Reinders M.E., van Gulik T.M., et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg 1994, 81:1642-1646.
24. Conlon KC AM. Pancreas cancer: Anatomy, staging systems, and techniques. Principles and Practice of Gastrointestinal Oncology 2008, 1008. Lipincott Williams and Wilkins, Philadelphia. (ed 2). D.P. D.J. Kelsen, S.E. Kern, B. Levin (Eds.).
25. Lu D.S., Reber H.A., Krasny R.M., et al. Local staging of pancreatic cancer: Criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. Am J Roentgenol 1997, 168:1439-1443.
26. Mollberg N., Rahbari N.N., Koch M., et al. Arterial resection during pancreatectomy for pancreatic cancer: A systematic review and meta-analysis. Ann Surg 2011, 254:882-893.
27. Katz M.H., Marsh R., Herman J.M., et al. Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013, 20:2787-2795.
28. Katz M.H.G., Pisters P.W.T., Evans D.B., et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008, 206:833-846.
29. Hsu C., Wolfgang C., Laheru D., et al. Early mortality risk score: Identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg 2012, 16:753-761.
30. Cameron J.L., Riall T.S., Coleman J., et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006, 244:10-15.
31. Mornex F., Girard N., Delpero J.-R., et al. Radiochemotherapy in the management of pancreatic cancer-Part I: Neoadjuvant treatment. Semin Radiat Oncol 2005, 15:226-234.
32. Hishinuma S., Ogata Y., Tomikawa M., et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006, 10:511-518.
33. Iacobuzio-Donahue C.A., Fu B., Yachida S., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27:1806-1813.
34. Garcea G., Dennison A.R., Pattenden C.J., et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. J Pancreas 2008, 9:99-132.
35. Riediger H., Keck T., Wellner U., et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009, 13:1337-1344.
36. Pawlik T.M., Gleisner A.L., Cameron J.L., et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007, 141:610-618.
37. La Torre M., Nigri G., Cavallini M., et al. The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2012, 19:2917-2923.
38. Cannon R.M., LeGrand R., Chagpar R.B., et al. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford) 2012, 14:228-235.
39. Sperti C., Pasquali C., Piccoli A., et al. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996, 83:625-631.
40. Chu C., Mazo A., Goodman M., et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 2010, 17:502-513.
41. Dawson S.I. Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer 2004, 100:149-155.
42. Min Park S., Kyung Lim M., Won Jung K., et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol 2007, 25:4835-4843.
43. Fleming J.B., Gonzalez R.J., Petzel M.B., et al. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg 2009, 144:216-221.
44. Kaiser M.H., Ellenberg S.S. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
45. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987, 59:2006-2010.
46. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-782. [discussion 82-4].
47. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001, 358:1576-1585.
48. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
49. O'Reilly E.M. Adjuvant therapy for pancreas adenocarcinoma. J Surg Oncol 2013, 107:78-85.
50. Abrams R.A., Lillemoe K.D., Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001, 358:1565-1566.
51. Katz M.H., Merchant N.B., Brower S., et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: Results from the ACOSOG Z5031 trial. Ann Surg Oncol 2011, 18:337-344.
52. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. J Am Med Assoc 2007, 297:267-277.
53. Neuhaus HR P, S Post, Gellert K, et al. Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 2008, ASCO Annual Meeting Proceedings 26(15S):LBA4504, 2008.
54. Stocken D.D., Buchler M.W., Dervenis C., et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005, 92:1372-1381.
55. Neoptolemos J.P., Stocken D.D., Bassi C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. J Am Med Assoc 2010, 304:1073-1081.
56. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. J Am Med Assoc 2008, 299:1019-1026.
57. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5 year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011, 18:1319-1326.
58. Showalter T.N., Winter K.A., Berger A.C., et al. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: A secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 2011, 81:1328-1335.
59. Berger A.C., Garcia M., Hoffman J.P., et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 2008, 26:5918-5922.
60. Berger A.C., Winter K., Hoffman J.P., et al. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys 2012, 84:e291-e297.
61. Abrams R.A., Winter K.A., Regine W.F., et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2012, 82:809-816.
62. Goodman K.A., Regine W.F., Dawson L.A., et al. Consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 2012, 83:901-908.
63. Hattangadi J.A., Hong T.S., Yeap B.Y., et al. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer 2009, 115:3640-3650.
64. Corsini M.M., Miller R.C., Haddock M.G., et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol 2008, 26:3511-3516.
65. Russ A.J., Weber S.M., Rettammel R.J., et al. Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. Ann Surg Oncol 2010, 17:371-376.
66. Herman J.M., Swartz M.J., Hsu C.C., et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008, 26:3503-3510.
67. Hsu C.C., Herman J.M., Corsini M.M., et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010, 17:981-990.
68. Van Laethem J.L., Hammel P., Mornex F., et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010, 28:4450-4456.
69. Kooby D., Gillespie T., Liu Y., et al. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: An appraisal of data from the National Cancer Data Base. Ann Surg Oncol 2013, 1-9.
70. Hazard L., Tward J.D., Szabo A., et al. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: Results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer 2007, 110:2191-2201.
71. Kimple R.J., Russo S., Monjazeb A., et al. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther 2012, 12:469-480.
72. Crane C.H., Varadhachary G.R., Yordy J.S., et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011, 29:3037-3043.
73. Bachet J.B., Marechal R., Demetter P., et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol 2012, 23:2327-2335.
74. Marechal R., Van Laethem J.L. Towards a tailored therapy in pancreatic cancer. Acta Gastroenterol Belg 2013, 76:49-56.
75. Bachet J.B., Marechal R., Demetter P., et al. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Eur J Cancer 2013, 49:2643-2653.
76. Hardacre J.M., Mulcahy M., Small W., et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: A phase 2 study. J Gastrointest Surg 2013, 17:94-100. [discussion p-1].
77. Link C.J., Seregina T., Atchison R., et al. Eliciting hyperacute xenograft response to treat human cancer: Alpha(1,3) galactosyltransferase gene therapy. Anticancer Res 1998, 18:2301-2308.
78. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
79. Katz M.G., Wang H., Fleming J., et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009, 16:836-847.
80. Papalezova K.T., Tyler D.S., Blazer D.G., et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?. J Surg Oncol 2012, 106:111-118.
81. Pingpank J., Hoffman J., Ross E., et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001, 5:121-130.
82. Abbott D.E., Merkow R.P., Cantor S.B., et al. Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. Ann Surg Oncol 2012, 19:3659-3667.
83. Abbott D.E., Tzeng C.W., Merkow R.P., et al. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol 2013.
84. Crane C.H., Varadhachary G., Pisters P.W., et al. Future chemoradiation strategies in pancreatic cancer. Semin Oncol 2007, 34:335-346.
85. Heinrich S., Pestalozzi B.C., Schafer M., et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:2526-2531.
86. Gillen S., Schuster T., Meyer Zum Buschenfelde C., et al. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267.
87. Katz M.H., Fleming J.B., Bhosale P., et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012, 118:5749-5756.
88. Hoffman J.P., Lipsitz S., Pisansky T., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1998, 16:317-323.
89. Mornex F., Girard N., Scoazec J.Y., et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys 2006, 65:1471-1478.
90. Le Scodan R., Mornex F., Girard N., et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: Feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009, 20:1387-1396.
91. Estrella J.S., Rashid A., Fleming J.B., et al. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012, 118:268-277.
92. Krishnan S., Rana V., Janjan N.A., et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007, 110:47-55.
93. Ko A.H., Quivey J.M., Venook A.P., et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:809-816.
94. Mukherjee S., Hudson E., Reza S., et al. Pancreatic cancer within a UK Cancer Network with special emphasis on locally advanced non-metastatic pancreatic cancer. Clin Oncol 2008, 20:535-540.
95. Florence Huguet T.A., Hammel Pascal, Artru Pascal, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326-331.
96. Chatterjee D., Katz M.H., Rashid A., et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome. Cancer 2012, 118:3182-3190.
97. Tsuruga Y., Kamachi H., Wakayama K., et al. Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer. World J Gastroenterol 2013, 19:2569.
98. Araujo R.L.C., Gaujoux S., Huguet F., et al. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB (Oxford) 2013, 15:574-580.
99. Cheng T.-Y., Sheth K., White R., et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol 2006, 13:66-74.
100. Chatterjee D., Rashid A., Wang H., et al. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol 2012, 36:552-559. 10.1097/PAS.0b013e318240c1c0.
101. Cui Y., Brosnan J.A., Blackford A.L., et al. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 2012, 18:6519-6530.
102. Torres-Roca J.F. A molecular assay of tumor radiosensitivity: A roadmap towards biology-based personalized radiation therapy. Pers Med 2012, 9:547-557.
103. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997, 225:621-633. [discussion 33-6].
104. Matsuoka L., Selby R., Genyk Y. The surgical management of pancreatic cancer. Gastroenterol Clin North Am 2012, 41:211-221.
105. Wahl R.L., Herman J.M., Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol 2011, 21:88-100.
106. Hall W.A., Colbert L.E., Liu Y., et al. The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer 2013, 119:2350-2357.
107. Zitvogel L., Apetoh L., Ghiringhelli F., et al. The anticancer immune response: Indispensable for therapeutic success?. J Clin Invest 2008, 118:1991-2001.
108. Heinemann V., Reni M., Ychou M., et al. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014, 40:118-128.
109. Timmerman R., Paulus R., Galvin J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. J Am Med Assoc 2010, 303:1070-1076.
110. Finkelstein S.E., Timmerman R., McBride W.H., et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011, 2011:439752.
111. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
112. Kozak K.R., Kachnic L.A., Adams J., et al. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys 2007, 68:1557-1566.
113. Hong T.S., Ryan D.P., Blaszkowsky L.S., et al. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys 2011, 79:151-157.
114. Chuong M.D., Springett G.M., Freilich J.M., et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013, 86:516-522.